Drug intelligence / Profile preview

cefmetazole + kanamycin + metronidazole

Development stage
Unknown
Lead developer
Astellas Pharma
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

This is a combination of three antibiotics—cefmetazole, kanamycin, and metronidazole—used together for broad-spectrum antimicrobial prophylaxis or treatment. - **Cefmetazole** is a cephamycin antibiotic (related to second-generation cephalosporins) with activity against Gram-positive, Gram-negative, and anaerobic bacteria. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins[6][8]. - **Kanamycin** is an aminoglycoside antibiotic that binds irreversibly to the 30S ribosomal subunit of bacteria, causing misreading of mRNA and inhibiting protein synthesis; it is mainly effective against aerobic Gram-negative bacteria[10]. - **Metronidazole** is a nitroimidazole antibiotic effective primarily against anaerobic bacteria and protozoa; it disrupts DNA structure in susceptible organisms leading to cell death[7]. This combination has been studied as perioperative prophylaxis in colorectal surgery (oral kanamycin + oral metronidazole preoperatively plus intravenous cefmetazole perioperatively), aiming to reduce surgical site infections by covering both aerobic and anaerobic pathogens commonly encountered in gastrointestinal procedures[1].

02

Targets

PBP (Penicillin-binding protein family)Bacterial Ribosome

Beyond the preview

Go deeper on cefmetazole + kanamycin + metronidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefmetazole + kanamycin + metronidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call